Haematology Watch

Chapter	Author/s
1. Stem cell transplant organisations	J. Apperley, A. Keating
2. Biological properties of haematopoietic stem cells	A. Wodnar-Filopowicz
3. Immunogenetics of allogeneic HSCT
3.1. The role of HLA in HSCT	J.M. Tiercy
3.2. KIR: Beneficial effects of natural killer cell alloreactivity in haploididentical HSCT	A. Velardi, A. Mancusi, F. Aversa, M.F. Martelli
3.3. Non-HLA immunogenetics and role in transplant outcome	A.M. Dickinson
4. JACIE accreditation of transplant centres	D. Samson
5. Sources and procurement of stem cells	J. Larghero, J. García, E. Gluckman
6. Principles of conditioning	A. Gratwohl
7. Transfusion policy	D.H. Pamphilon
8. Supportive care	T. Masszi
9. Early complications after HSCT	E. Carreras
10. Infections after HSCT	C. Cordonnier
11. Graft versus host disease	A. Devergie
12. Long term survivorship, general health status, quality of life and late complications after HSCT	A. Tichelli, C-P. Schwarze, G.Socié
13. The value of molecular monitoring in haematological malignancy; minimal residual disease (MRD), relapse and chimerism	S.R. McCann, M. Lawler
14. Immunotherapy post-transplant
14.1. Immunotherapy post-transplant for infections	M. Kapp, G.U. Grigoleit, H. Einsele
14.2. Adoptive cellular immunotherapy to harness post-transplant alloreactivity	E. Nadal
15. Immune reconstitution after allogeneic HSCT	A. Toubert
16. Psychosocial aspects of HSCT	A. Kiss
17. Indications and current practice for allogeneic and autologous HSCT for haematological diseases, solid tumours and immune disorders	A. Gratwohl, P.Ljungman
18. Statistical evaluation of HSCT data	R.M. Szydlo
19. Methodology of conducting academic clinical trialsin Europe	Z. Doran
20. HSCT for acute myeloid leukaemia in adults	R. Varaldo, F. Frassoni
21. HSCT for acute lymphoblastic leukaemia in adults	N. Gökbuget, D. Hoelzer
22. HSCT for myelodysplasia in adults	T. de Witte, G. Sanz
23. HSCT for chronic myeloid leukaemia in adults	D. Niederweiser
24. HSCT for myeloproliferate disorders in adults	P. Guardiola
25. HSCT for chronic lymphocytic leukaemia in adults	P. Dreger
26. HSCT for multiple myeloma in adults	J.A. Pérez-Simon, J. San Miguel
27. HSCT for primary amyloidosis in adults	J. Esteve
28. HSCT for high-grade non-Hodgkin's lymphoma in adults	A. Johnston, B. Coiffier
29. HSCT for low-grade non-Hodgkin's lymphoma in adults	J.G. Cribben
30. HSCT for Hodgkin's lymphoma in adults	A. Sureda
31. HSCT for solid tumours in adults	M. Bregni
32. HSCT for autoimmune diseases in adults	R. Saccardi, D. Farge
33. HSCT for aplastic anaemia in adults	J. Passweg, A. Bacigalupo, A. Locasciulli
34. HSCT for tissue regeneration in adults	F. Prosper
35. HSCT for acute myeloid leukaemia in children	G. Dini, M. Miano
36. HSCT for acute lymphoblastic leukaemia in children	T. Klingebiel, P. Bader
37. HSCT for myelodysplastic syndromes in children	F. Locatelli, C.M. Niemeyer
38. HSCT for chronic myeloproliferate disorders in children	F. Locatelli, P. Merli
39. HSCT for lymphomas in children	M. Miano, G. Dini
40. HSCT for children with severe combined immunodificiencies (SCID)	M. Cavazzana-Calvo, W. Friedrich, A. Fischer
41. HSCT for inborn errors of metabolism	J.J. Boelens, R.F. Wynn, M. Bierings
42. HSCT for hereditary bone marrow failure syndromes	E. Gluckman, J.E. Wagner
43. HSCT in the haemoglobinopathies	I.A.G. Roberts, J. de la Fuente
Abbreviations
Appendix: EBMT Officers, Coordination Offices, Committees, Working Parties, Nurses Group Board, Affiliated Organisations/Websites